A popular corticosteroid inhaler used to treat asthma and other conditions is being discontinued, and despite generic versions now available, health experts are warning patients to plan ahead for ...

One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, potentially leaving patients, healthcare providers and insurers scrambling.

GlaxoSmithKline plc today announced that the Food and Drug Administration has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for ...

Arnuity™ Ellipta® now available in the US for once-daily treatment of asthma. Incruse® Ellipta® now available in the US for once-daily treatment for COPD. GlaxoSmithKline plc (LSE/NYSE: GSK) today ...

The FDA has approved fluticasone furoate inhalation powder as a once-daily corticosteroid for maintenance treatment of asthma in patients aged 12 and older, according to a press release. Fluticasone ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ARNUITY ELLIPTA contains the active ingredient fluticasone furoate.

LONDON, Aug. 20, 2014 /PRNewswire/ -- GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta ® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS ...

Fluticasone furoate 50mcg, 100mcg, 200mcg; per inhalation; dry pwd for oral inhalation. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist for acute symptoms; monitor for ...